Katelyn A. Bruno
Mayo Clinic
61 Papers
34 Citations
Katelyn A. Bruno is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 30 publications. Previous affiliations of Katelyn A. Bruno include Johns Hopkins University.
Chat about Author
Papers
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Michael J. Joyner,Rickey E. Carter,Jonathon W. Senefeld,Stephen A. Klassen,John Mills,Patrick W. Johnson,Elitza S. Theel,Chad C. Wiggins,Katelyn A. Bruno,Allan M. Klompas,Elizabeth R. Lesser,Katie L. Kunze,Matthew A. Sexton,Juan C. Diaz Soto,Sarah E. Baker,John R. A. Shepherd,Noud van Helmond,Nicole C. Verdun,Peter W. Marks,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Robert F. Rea,David O. Hodge,Vitaly Herasevich,Emily R. Whelan,Andrew J. Clayburn,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Nigel Paneth,De Lisa Fairweather,R. Scott Wright,Arturo Casadevall +39 more
TL;DR: In this paper, the anti-SARS-CoV-2 antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19 were determined based on a U.S. national registry, and the primary outcome was death within 30 days after plasma transfusion.
512
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
Michael J. Joyner,R. Scott Wright,DeLisa Fairweather,Jonathon W. Senefeld,Katelyn A. Bruno,Stephen A. Klassen,Rickey E. Carter,Allan M. Klompas,Chad C. Wiggins,John R. A. Shepherd,Robert F. Rea,Emily R. Whelan,Andrew J. Clayburn,Matthew R. Spiegel,Patrick W. Johnson,Elizabeth R. Lesser,Sarah E. Baker,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,David O. Hodge,Katie L. Kunze,Matthew R. Buras,Matthew N.P. Vogt,Vitaly Herasevich,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Nigel Paneth,Nicole C. Verdun,Peter W. Marks,Arturo Casadevall +35 more
TL;DR: Early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and given the deadly nature of COVID 19 and the large population of critically-ill patients, the mortality rate does not appear excessive.
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.
Michael J. Joyner,Katelyn A. Bruno,Stephen A. Klassen,Katie L. Kunze,Patrick W. Johnson,Elizabeth R. Lesser,Chad C. Wiggins,Jonathon W. Senefeld,Allan M. Klompas,David O. Hodge,John R. A. Shepherd,Robert F. Rea,Emily R. Whelan,Andrew J. Clayburn,Matthew R. Spiegel,Sarah E. Baker,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Vitaly Herasevich,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Noud van Helmond,Brian P. Butterfield,Matthew A. Sexton,Juan C. Diaz Soto,Nigel Paneth,Nicole C. Verdun,Peter W. Marks,Arturo Casadevall,De Lisa Fairweather,Rickey E. Carter,R. Scott Wright +39 more
TL;DR: New data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of CO VID-19 is more likely to reduce mortality.
410
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience
Michael J. Joyner,Jonathon W. Senefeld,Stephen A. Klassen,John Mills,Patrick W. Johnson,Elitza S. Theel,Chad C. Wiggins,Katelyn A. Bruno,Allan M. Klompas,Elizabeth R. Lesser,Katie L. Kunze,Matthew A. Sexton,Juan C. Diaz Soto,Sarah E. Baker,John R. A. Shepherd,Noud van Helmond,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Robert F. Rea,David O. Hodge,Vitaly Herasevich,Emily R. Whelan,Andrew J. Clayburn,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Nigel Paneth,DeLisa Fairweather,R. Scott Wright,Rickey E. Carter,Arturo Casadevall +37 more
TL;DR: The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for convalescent plasma in the treatment of hospitalized COVID-19 patients.
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
Christina A. von Roemeling,Christina A. von Roemeling,Yifan Wang,Yaqing Qie,Yaqing Qie,Hengfeng Yuan,Hengfeng Yuan,Hai Zhao,Xiujie Liu,Zhaogang Yang,Mingming Yang,Weiye Deng,Katelyn A. Bruno,Charles Chan,Andrew S. Lee,Andrew S. Lee,Stephen S. Rosenfeld,Kyuson Yun,Aaron J. Johnson,Duane Mitchell,Wen Jiang,Betty Y.S. Kim +21 more
TL;DR: In glioblastoma mouse models, temozolomide improves the phagocytosis effect of CD47 blockade in APCs and results in the activation of adaptive anti-tumour responses, revealing a dynamic relationship between innate and adaptive immune regulation in tumours.